Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients

NCT ID: NCT02076659

Last Updated: 2018-05-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-09-30
• Study Completion Date: 2017-04-13

Brief Summary

Phase I, multicenter, open-label, dose escalation study to test the efficacy and safety of F8IL10 and methotrexate when given as a combination in rheumatoid arthritis patients.

Detailed Description

The study is designed to explore whether F8IL10 can be safely administered in combination with standard-dose of MTX in patients with active rheumatoid arthritis and to determine the recommended dose of F8IL10 when combined with MTX.

As soon as the MTD/RD is determined, an additional 12 patients will be randomized (6+6) between F8IL10 (RD) and placebo to further investigate the safety and pharmacacodynamics profile of the study treatment.

Methotrexate (MTX) will be administered as concomitant medication in the dose escalation as well as in the randomized part of the study.

Conditions

Rheumatoid Arthritis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

F8IL10 + MTX

Ten cohorts of 3-6 RA patients will be treated at increasing doses per cohort of F8IL10 plus fixed doses of MTX and folic acid.

An additional 12 patients will be randomized (6+6) in a double blind, placebo controlled cohort with F8IL10 given at RD and placebo. In both arms, MTX will be administered as concomitant medication.

In all coohorts a stable dose of folic acid (5 mg) will be administered on Day 2.

Group Type: EXPERIMENTAL

F8IL10

Intervention Type: DRUG

Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study.

F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent.

Methotrexate

Intervention Type: DRUG

Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.).

Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent.

Interventions

F8IL10

Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study.

F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent.

Intervention Type: DRUG

Methotrexate

Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.).

Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients aged ≥ 18 and < 75 years.

2. Diagnosis of RA according to ACR criteria (1987) with a disease duration exceeding 12 months.

3. Active RA (DAS28 ≥ 3.2) for ≥ 4 months at time of signing informed consent.

4. Receiving treatment on an outpatient basis.

5. MTX at 10-15 mg/w for a period ≥ 8 weeks prior to treatment.

6. Inadequate clinical response to at least one anti-TNF therapy applied for at least 4 months.

7. If patients are receiving an oral corticosteroid, the dose must have been stable for at least 25 out of 28 days prior to study treatment and the dose must be less than 10 mg/day (prednisolone equivalent).

8. All acute toxic effects of any prior therapy must have returned to classification "mild" according to RCTC V.2.0 [1] .

9. Sufficient hematologic, liver and renal function:

• Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, hemoglobin (Hb) ≥ 9.5 g/dL
• Alkaline phosphatase (AP), alanine aminotransferase (ALT) and or aspartate aminotransferase (AST) ≤ 3 x upper limit of normal range (ULN), and total bilirubin ≤ 2.0 mg/dL (34.2 µmol/L)
• Creatinine ≤ 1.5 ULN or 24 h creatinine clearance ≥ 50 mL/min

10. Documented negative test for human immunodeficiency virus, HBV, and HCV. For patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative serum HBV DNA is required.

11. Male and female patients, who are potentially fertile, must agree to use adequate contraceptive methods at the beginning of the screening visit that must be continued until 3 months following the last treatment with study drug.

12. Negative serum pregnancy test (for women of child-bearing potential only) at screening.

13. Signed and dated Ethics Committee-approved Informed Consent Form indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the study.

14. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria

1. Presence of active infections (e.g. requiring antibiotic therapy) or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or would interfere with the study objectives or conduct.

2. Pregnancy, lactation or unwillingness to use adequate contraceptive methods.

3. Active or latent tuberculosis (TB).

4. Chronic active hepatitis or active autoimmune diseases other than RA.

5. History of currently active primary or secondary immounodeficiency.

6. HIV Infection.

7. Acute or chronic-active infection with HBV or HCV, as assessed by serology or HBV DNA.

8. Evidence of active malignant disease at screening or advanced malignancies diagnosed within the previous 5 years.

9. Any previous treatment with alkylating agents, such as cyclophosphamide or chlorambucil or with total lymphoid irradiation.

10. History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.

11. Treatment with warfarin or other coumarin derivatives.

12. Heart insufficiency (> Grade II, New York Heart Association (NYHA) criteria).

13. Irreversible cardiac arrhythmias requiring permanent medication.

14. Clinically significant (to clinical investigator's discretion) abnormalities in baseline MUGA, ECHO or ECG analyses.

15. Uncontrolled hypertension.

16. Ischemic peripheral vascular disease (Grade IIb-IV).

17. Severe diabetic retinopathy.

18. Major trauma including surgery within 4 weeks of administration of study treatment.

19. Known history of allergy or other intolerance to IL10, MTX, folic acid or other drugs based on human proteins/peptides/antibodies.

20. In vivo exposure to monoclonal antibodies for biological therapy (e.g., adalimumab,infliximab golimumab, tocilizumab, certolizumab pegol) less than 8 weeks prior to administration of study medication.

21. Treatment with rituximab less than 4 months prior to administration of study medication.

22. Treatment with fusion proteins (e.g. abatacept, etanercept) less than 4 weeks prior to administration of study medication.

23. Treatment with any investigational agent within the 6 weeks before study treatment.

24. Immunization with a live/attenuated vaccine within 4 weeks prior to baseline.

25. Growth factors or immunomodulatory agents, including anakinra, within 7 days of the administration of study treatment.

26. Neuropathy > Grade 1 or Neuropathies or other painful conditions (not RA-related) that might interfere with pain evaluation.

27. Patients required to be treated with corticosteroids at a dose > 10 mg/day or with immunosuppressant drugs other than MTX on a long-term basis. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criterion.

28. History of alcohol, drug or chemical substance abuse within the 6 months prior to screening.

29. Body weight of >100 kg.

30. Any condition that in the opinion of the investigator could hamper compliance with the study protocol.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Philogen S.p.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mauro Galeazzi, Prof

Role: PRINCIPAL_INVESTIGATOR

Siena University Hospital

Locations

Policlinico San Matteo, Pavia

Pavia, , Italy

Pisa University Hospital

Pisa, , Italy

Azienda Ospedaliera San Camillo-Forlanini Roma

Roma, , Italy

Policlinico A. Gemelli, Università Cattolica del Sacro Cuore

Roma, , Italy

Siena University Hospital

Siena, , Italy

Countries

Italy

Other Identifiers

2008-008729-31

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

PH-F8IL10-02/08

Identifier Type: -

Identifier Source: org_study_id